Market Research Logo

Global Heparin Market 2016-2020

About Heparin

Heparin, a disaccharide anticoagulant or blood thinner, prevents the formation of blood clots. It is produced in the body by basophils and mast cells. It is stored within mast cells and secreted at the injury site. Though it has no effect on already formed clots, it enables the body's natural clot lysis mechanisms to dissolve clots. It can also be taken from outside as a drug. Heparin can be derived from natural sources such as pig intestine and bovine lungs.

Heparin is divided into two types based on the fractionation process. Both types have medical use, with the selection done based on preference for a particular condition.

  • UFH: It is directly obtained from natural sources, without undergoing any fractionation.
  • LMWH: It is derived by depolymerizing UFH. The pharmacodynamics properties of LMWH are more predictable when compared to UFH.
  • Apart from these, another category of molecules, ULMWH are available. They are structurally related to LMWHs, but differ in the composition of monosaccharides and oligosaccharides. Therefore, they have different average molecular weights from LMWH.

    Technavio’s analysts forecast the global heparin market to grow at a CAGR of 4.74% during the period 2016-2020.

    Covered in this report

    The report covers the present scenario and the growth prospects of the global heparin market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generics used to treat disorders.

    The market is divided into the following segments based on geography:
    • Americas
    • APAC
    • EMEA
    Technavio's report, Global Heparin Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

    Key vendors
    • GlaxoSmithKline plc (GSK)
    • Leo Pharma A/S
    • Pfizer Inc.
    • Sanofi
    Other prominent vendors
    • Alchemi
    • Baxter
    • BMS
    • Boehringer Ingelheim
    • Celgene
    • Cosmo Pharmaceuticals
    • Dr.Reddy's Laboratories
    • Eisai
    • Fresenius
    • GSK
    • Hospira
    • Laboratorios Rovi Pharmaceuticals
    • Lee's Pharmaceutical
    • Momenta Pharmaceuticals
    • Mylan
    • Novartis
    • Ockham Biotech
    • Perospher
    • PolyMedix
    • Portola Pharmaceutical
    • ProStrakan Group
    • Sagent Pharmaceticals
    • Sigma Tau Pharmaceuticals
    • UCB
    • Urigen Pharmaceuticals
    Market driver
    • Growing prevalence of diseases
    • For a full, detailed list, view our report
    Market challenge
    • Extensive use of generic products due to patent expirations
    • For a full, detailed list, view our report
    Market trend
    • Expected exploitation of new therapeutic use
    • For a full, detailed list, view our report
    Key questions answered in this report
    • What will the market size be in 2020 and what will the growth rate be?
    • What are the key market trends?
    • What is driving this market?
    • What are the challenges to market growth?
    • Who are the key vendors in this market space?
    • What are the market opportunities and threats faced by the key vendors?
    • What are the strengths and weaknesses of the key vendors?


    Press Release

    Technavio Announces the Publication of its Research Report – Global Heparin Market 2016-2020

    Technavio recognizes the following companies as the key players in the Global Heparin Market: GlaxoSmithKline plc (GSK), Leo Pharma A/S, Pfizer Inc., and Sanofi.

    Other Prominent Vendors in the market are: Alchemi, Baxter, BMS, Boehringer Ingelheim, Celgene, Cosmo Pharmaceuticals, Dr.Reddy's Laboratories, Eisai, Fresenius, GSK, Hospira, Laboratorios Rovi Pharmaceuticals, Lee's Pharmaceutical, Momenta Pharmaceuticals, Mylan, Novartis, Ockham Biotech, Perospher, PolyMedix, Portola Pharmaceutical, ProStrakan Group, Sagent Pharmaceticals, Sigma Tau Pharmaceuticals, UCB, and Urigen Pharmaceuticals.

    Commenting on the report, an analyst from Technavio’s team said: “Introduction of new heparin antidotes into the market can counteract the adverse events caused by heparin, fueling the growth of the market.”

    According to the report, Increase in the prevalence of DVT and thrombosis along with the increased inclination shown toward surgeries requiring heparin administration drive the growth of the market.

    Further, the report states that patent expiries of major marketed products leads to a decline in sales, affecting the overall market growth.

    Companies Mentioned

    GlaxoSmithKline plc (GSK), Leo Pharma A/S, Pfizer Inc., Sanofi, Alchemi, Baxter, BMS, Boehringer Ingelheim, Celgene, Cosmo Pharmaceuticals, Dr.Reddy's Laboratories, Eisai, Fresenius, GSK, Hospira, Laboratorios Rovi Pharmaceuticals, Lee's Pharmaceutical, Momenta Pharmaceuticals, Mylan, Novartis, Ockham Biotech, Perospher, PolyMedix, Portola Pharmaceutical, ProStrakan Group, Sagent Pharmaceticals, Sigma Tau Pharmaceuticals, UCB, Urigen Pharmaceuticals.

    • Executive summary
      • Highlights
    • Scope of the report
      • Market overview
      • Top-vendor offerings
        • Table Product offerings
    • Market research methodology
      • Research methodology
      • Economic indicators
    • Introduction
      • Key market highlights
      • Key buying criteria
        • Table Key buying criteria for heparin drugs
    • Heparin: An overview
      • Table Differences between porcine heparin and bovine heparin
      • Table Process of blood coagulation
      • Mechanism of action (MOA)
        • Table Mechanism of action of heparin
      • Limitations of heparin use
      • Clinical uses of heparin
      • Branded drug profiles
    • Pipeline portfolio
      • Table Pipeline portfolio: Heparin drugs
      • LMW Heparin MMX
      • URG101
      • Heparin
      • Heparin plus dexoyribonuclease (DNAse)
      • Heparin plus other inhaled drug
    • Market landscape
      • Global anticoagulant drugs market
        • Table Market share of global heparin market in global anticoagulant drugs market 2015
        • Table Global anticoagulant drugs market 2015-2020 ($ billions)
      • Global heparin market
        • Table Global heparin market 2015-2020 ($ billions)
      • Five forces analysis
        • Table Five forces analysis
    • Heparin use in CPB surgery
      • CPB
      • Heparin use in CPB surgery
      • Global heparin market in CPB surgeries
        • Table Global heparin market in CPB surgeries 2015-2020 ($ millions)
    • Heparin API market
      • China: Heparin API market
    • Suppliers of crude heparin
      • Table Process of crude heparin production in China
      • FDA guidance for heparin suppliers
    • Market segmentation by product type
      • Table Segmentation of global heparin market by product type 2015
      • UFH
      • LMWH
      • ULMWH
    • Market segmentation by ROA
      • Table Segmentation of global heparin market by ROA
      • IV injection/infusion
      • SC injection
    • Geographical segmentation
      • Global heparin market by geographical segmentation 2015-2020
        • Table Segmentation of global heparin market based on geography 2015
        • Table Global heparin market revenue by geography 2015-2020 ($ billions)
        • Table Global heparin market by geography 2015-2020
      • Heparin market in EMEA
        • Table Heparin market in EMEA 2015-2020 ($ billions)
      • Heparin market in Americas
        • Table Heparin market in Americas 2015-2020 ($ billions)
      • Heparin market in APAC
        • Table Heparin market in APAC 2015-2020 ($ billions)
        • Table Global heparin market: YoY growth and revenue based on geography 2015-2020
    • Market drivers
      • Growing prevalence of diseases
      • Increase in supply chains of crude heparin
      • Reintroduction of bovine heparin by US FDA
    • Impact of drivers
      • Table Impact of drivers
    • Market challenges
      • Extensive use of generic products due to patent expirations
      • Risk of side-effects
      • Shortage of crude heparin
      • Threat of adulteration
      • Presence of well-established oral anticoagulants
    • Impact of drivers and challenges
      • Table Impact of drivers and challenges
    • Market trends
      • Expected exploitation of new therapeutic use
      • Strategic alliances
      • Increase in R&D
      • Entry of new heparin antidotes
    • Vendor landscape
      • Competitive scenario
      • Market analysis 2015
      • Sanofi
        • Table Sanofi: YoY revenue and growth rate of Lovenox 2013-2015 ($ billions)
        • Table Geographical segmentation of Lovenox 2015
        • Table Sanofi: Key takeaways
      • Pfizer
        • Table Pfizer: YoY revenue and growth rate of Fragmin 2013-2015 ($ millions)
        • Table Geographical segmentation of Fragmin by revenue 2015
        • Table Pfizer: Key takeaways
      • Aspen
        • Table Aspen: Key takeaways
      • LEO Pharma
        • Table LEO Pharma: Key takeaways
      • Other prominent vendors
    • Appendix
      • List of abbreviations
    • Explore Technavio

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report